New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2012
05:55 EDTACTC, ACTC, SNY, SNY, ATHX, ATHX, BAX, BAX, GENZ, GENZ, PFE, PFE, NVS, NVS, PSTI, PSTI, LIFE, LIFE, CYTX, CYTX, SGMO, SGMOGlobal Technology to host a summit
8th GTC Stem Cell Summit is being held in Boston on April 19-20.
News For ACTC;CYTX;LIFE;PSTI;NVS;PFE;GENZ;BAX;ATHX;SNY;SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 27, 2015
06:19 EDTPFE, NVS, SNYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
10:00 EDTSGMOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:52 EDTNVSEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
09:18 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:57 EDTBAXBaxter still sees separation costs just above $300M, or 2% of sales
Subscribe for More Information
08:41 EDTBAXBaxter says separation of two companies on track for mid-2015
Subscribe for More Information
08:15 EDTCYTXCytori reports preclinical data on use of cell therapy in burn/radiation wounds
Subscribe for More Information
07:21 EDTBAXBaxter sees Q2 continuing ops EPS 92c-96c, consensus $1.01
The company expects sales growth of approximately 1%, excluding the impact of foreign currency. Including the impact of foreign currency, the company expects sales to decline approximately 9%-10%. Consensus is $3.92B. Baxter also expects earnings from continuing operations, before special items, of 92c-96c per diluted share. The Q2 earnings guidance excludes approximately 8c per diluted share of projected intangible amortization expense. Reconciling for the inclusion of intangible asset amortization results in expected GAAP earnings of 84c-88c per diluted share, before other special items, for the quarter.
07:01 EDTBAXBaxter reports Q1 adjusted EPS $1.00, consensus 88c
Subscribe for More Information
06:18 EDTSGMOSangamo initiated with an Outperform at BMO Capital
Subscribe for More Information
05:25 EDTNVSNovartis backs FY15 revenue guidance of growth in mid-single digits
Subscribe for More Information
05:22 EDTNVSNovartis reports Q1 Core EPS $1.33, consensus $1.10
Subscribe for More Information
April 22, 2015
16:10 EDTSGMOSangamo sees FY15 revenue $60M-$70M, consensus $67.71M
16:09 EDTSGMOSangamo reports Q1 EPS (8c), consensus (14c)
Reports Q1 revenue $13.5M, consensus $12.5M.
15:50 EDTBAXNotable companies reporting before tomorrow's open
Subscribe for More Information
10:02 EDTSNYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded on post-merger outlook at Bernstein... Amazon.com (AMZN) upgraded to Buy, price target raised to $450 at Monness Crespi... BNP Paribas (BNPQY) upgraded to Overweight from Equal Weight at Morgan Stanley... Dolby (DLB) upgraded to Overweight from Neutral at JPMorgan... First Defiance (FDEF) upgraded to Outperform from Market Perform at Raymond James... Gran Tierra (GTE) upgraded to Buy from Neutral at Dundee... Grupo Aval (AVAL) upgraded to Buy from Neutral at Goldman... Manhattan Associates (MANH) upgraded to Buy from Hold at Benchmark Co.... Marriott (MAR) upgraded to Buy from Neutral at MKM Partners... Masco (MAS) upgraded to Outperform from Market Perform at FBR Capital... Nokia (NOK) upgraded on post-merger outlook at Bernstein... Packaging Corp. (PKG) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Sector Perform from Underperform at RBC Capital... Rogers Communications (RCI) upgraded to Buy from Neutral at BofA/Merrill... Sanofi (SNY) upgraded to Neutral from Sell at Citigroup... Select Comfort (SCSS) upgraded to Outperform from Neutral at Wedbush... UniCredit (UNCFF) upgraded to Buy from Sell at Berenberg... Zions Bancorp (ZION) upgraded to Outperform from Market Perform at FBR Capital.
08:49 EDTBAXCTI BioPharma, Baxter to announce Phase 3 pacritinib data at ASCO late-breaker
CTI BioPharma (CTIC) and Baxter (BAX) announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology, or ASCO, meeting, to be held May 29-June 2 in Chicago. These data have also been selected as part of this year's official ASCO press briefing titled "Targeted Therapy" to be held on Saturday, May 30, at 8:00 am CT, the companies said.
07:07 EDTSNYEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
06:52 EDTSNYSanofi upgraded to Neutral from Sell at Citigroup
Subscribe for More Information
05:48 EDTATHXStocks with implied volatility movement; CSX ATHX
Stocks with implied volatility movement; CSX (CSX) 40, Athersys (ATHX) 151 according to iVolatility.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use